Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 4Phase 1 3

Status

Recruiting 4Not yet recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 2Neoplasms 1Melanoma 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × capivasertib × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT05563220 2026-01-06

ELEVATE

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
435 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡